Mission Wealth Management LP Acquires 601 Shares of Stryker Co. (NYSE:SYK)

Mission Wealth Management LP raised its holdings in shares of Stryker Co. (NYSE:SYK) by 7.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,504 shares of the medical technology company’s stock after acquiring an additional 601 shares during the quarter. Mission Wealth Management LP’s holdings in Stryker were worth $3,062,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of SYK. Kohmann Bosshard Financial Services LLC purchased a new position in Stryker during the fourth quarter valued at $25,000. Dunhill Financial LLC raised its stake in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after buying an additional 37 shares during the period. Centricity Wealth Management LLC purchased a new position in shares of Stryker during the 4th quarter valued at about $30,000. BankPlus Trust Department bought a new position in shares of Stryker during the 4th quarter valued at approximately $33,000. Finally, Darwin Wealth Management LLC purchased a new stake in Stryker in the 3rd quarter worth approximately $36,000. Institutional investors own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on SYK shares. The Goldman Sachs Group lifted their price target on shares of Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a report on Thursday, January 30th. StockNews.com cut shares of Stryker from a “buy” rating to a “hold” rating in a research note on Tuesday, February 25th. Argus set a $450.00 price target on Stryker in a research note on Monday, February 3rd. JMP Securities restated a “market perform” rating on shares of Stryker in a research report on Tuesday, February 18th. Finally, Stifel Nicolaus lifted their target price on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $422.15.

Stryker Price Performance

Stryker stock opened at $394.53 on Tuesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The stock has a market cap of $150.54 billion, a price-to-earnings ratio of 50.84, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96. The firm has a 50-day moving average of $381.06 and a two-hundred day moving average of $371.92. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the company earned $3.46 EPS. On average, research analysts forecast that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.85%. Stryker’s payout ratio is currently 43.30%.

Insider Buying and Selling

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.